Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Gentel Rolls Out APiX Disease Profiling Kit

Gentel Biosciences, a provider of proteomics discovery medical device tools, has introduced APiX Disease Profiling Kit, a cost-effective single-capture antibody array detection kit suitable for profiling disease-related proteins across multiple disease states.

The kit combines Gentel’s APiX chromogenic detection platform and Clontech’s research-validated Antibody 380 array technology to help scientists study tumor-associated antigens, compare proteomic and transcriptomic data, and perform target identification and validation using an alternate readout to current fluorescent offerings.

The kit measures data using the Gentel Proteomics Multi-System and AthenaQuant analysis suite of software, which helps to bring proteomics available to all biological researchers.

Gentel said that the APiX kit detects a variety of proteins representing a broad range of biological functions, including signal transduction, cell-cycle regulation, and apoptosis related to cancer, cardiovascular, neurodegenerative, viral infection, obesity, aging and immunological abnormalities.

The differences can be detected in protein abundance between two individual samples from biological fluids, cells, and whole tissue.

Alex Vodenlich, president and CEO of Gentel, said: “This launch expands the application of our APiX chromogenic detection technology to include proven high density antibody arrays. The benefits here are clear; researchers can now discover and profile disease states at the protein level without the requirement of special training or expensive fluorescent or bead-based systems.

“We’re bridging the technology gap between genomics and proteomics research by helping scientists with little or no expertise in proteomics perform high throughput analysis of proteomic profiles at a fraction of cost and time involved with existing platforms.”